Walleye Capital LLC Purchases New Position in MacroGenics, Inc. (NASDAQ:MGNX)

Walleye Capital LLC bought a new position in MacroGenics, Inc. (NASDAQ:MGNXGet Rating) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 213,978 shares of the biopharmaceutical company’s stock, valued at approximately $1,885,000. Walleye Capital LLC owned about 0.35% of MacroGenics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Point72 Hong Kong Ltd raised its stake in shares of MacroGenics by 101.9% in the fourth quarter. Point72 Hong Kong Ltd now owns 5,361 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 2,706 shares during the last quarter. Teacher Retirement System of Texas bought a new position in MacroGenics in the first quarter valued at about $89,000. E Fund Management Co. Ltd. acquired a new stake in MacroGenics in the first quarter worth about $92,000. Quantbot Technologies LP raised its holdings in MacroGenics by 188.2% during the 1st quarter. Quantbot Technologies LP now owns 11,900 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 7,771 shares during the last quarter. Finally, Walleye Trading LLC acquired a new position in MacroGenics during the 1st quarter valued at about $119,000.

MacroGenics Trading Down 2.5 %

MGNX stock opened at $3.45 on Friday. The business’s 50-day moving average price is $3.98 and its two-hundred day moving average price is $5.28. The firm has a market cap of $212.03 million, a PE ratio of -0.97 and a beta of 1.96. MacroGenics, Inc. has a 1-year low of $2.13 and a 1-year high of $22.78.

MacroGenics (NASDAQ:MGNXGet Rating) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.30. The firm had revenue of $26.01 million for the quarter, compared to analyst estimates of $14.59 million. MacroGenics had a negative return on equity of 102.68% and a negative net margin of 326.76%. On average, analysts forecast that MacroGenics, Inc. will post -2.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MGNX. StockNews.com raised shares of MacroGenics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. HC Wainwright reduced their price target on MacroGenics from $35.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, September 12th. BMO Capital Markets lowered MacroGenics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $31.00 to $4.00 in a research report on Monday, July 11th. JMP Securities reduced their price target on MacroGenics from $24.00 to $20.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 12th. Finally, Barclays reduced their price target on MacroGenics to $8.00 in a research report on Monday, August 15th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, MacroGenics presently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

MacroGenics Company Profile

(Get Rating)

MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Read More

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNXGet Rating).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.